SENO Targets European Growth With Nicotine and CBD Oral Thin Films at Paris Expo

New updates have been reported about SENO.

SENO is accelerating its European expansion by showcasing its nicotine oral thin film platform and debuting a CBD concept film at the International Vaping Exhibition in Paris, positioning the company at the center of the region’s shift toward discreet, smoke-free delivery formats. The firm highlighted that tightening European regulations on traditional nicotine products are driving demand for portable, compliant, and precisely dosed alternatives, areas where its oral films are designed to compete.

The company has spent recent years building a more structured operating footprint across multiple European markets, investing in compliance systems and standardizing product frameworks to align with differing national rules while preserving consistency in quality and dosing. At the Paris event, SENO reported strong interest from distributors and buyers in France, Germany, and Italy who are assessing oral film platforms as scalable solutions that can plug into existing retail and logistics networks without significant infrastructure upgrades.

SENO’s nicotine oral thin film technology is framed as part of the broader smoke-free category, emphasizing controlled delivery and regulatory compatibility, both critical to gaining acceptance from policymakers and health-conscious consumers. Industry feedback at the show indicated growing recognition of oral films as a viable complement or alternative to current nicotine replacement and vaping products, which could support SENO’s efforts to deepen distribution partnerships and secure repeat orders.

Strategically, SENO is also diversifying beyond nicotine by unveiling a CBD Concept Oral Thin Film focused on potential use cases such as relaxation and stress management within the wellness segment. While still in development, the CBD concept leverages the same proprietary carrier system to deliver cannabinoids in a controlled, discreet format and drew attention from partners exploring new high-margin functional categories.

Management positions this move as an extension of SENO’s technology platform into adjacent markets where precision dosing, portability, and regulatory clarity are critical to scale. The company indicates that continued investment in formulation science and oral delivery innovation is central to its long-term growth strategy, aiming to streamline entry into additional geographies and categories as regulatory frameworks evolve. A SENO representative underscored this direction by stating that the firm intends to push thin film technology from nicotine alternatives into broader wellness applications, aligning product development with global compliance requirements and shifting consumer preferences.